CTIS2024-512217-40-00进行中（未招募）1 期
An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study - TAS-120-404
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. Provide written informed consent., 2. Receiving futibatinib as monotherapy or in combination with fulvestrant in an antecedent futibatinib study and deriving clinical benefit with no undue risk as assessed by the investigator., 3. Women of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to receiving treatment under this protocol. (Female patients are not considered to be of childbearing potential if they are permanently sterile [hysterectomy, bilateral salpingectomy, or bilateral oophorectomy] or are postmenopausal [no menses for 12 months without an alternative medical cause]). Both males and females of reproductive potential must agree to use effective birth control during study treatment and for a specified time after the last dose of study treatment., 4. Ability to take medications orally (PO) (feeding tube is not permitted).
排除标准
- •1. Has met any discontinuation criteria within the antecedent futibatinib study.
研究者
相似试验
招募中
2 期
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or RearrangementAdvanced Cholangiocarcinoma Harboring FGFR2 Gene Fusion or RearrangementsJPRN-jRCT2051230018Elsayed Hamdy13
招募中
1 期
FOENIX-CCA4CTIS2023-503665-39-00Taiho Oncology Inc.120
进行中（未招募）
2 期
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.Advanced/Metastatic CancerNCT06506955Taiho Oncology, Inc.15
进行中（未招募）
1 期
An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europeeuroendocrine TumoursMedDRA version: 21.0Level: PTClassification code 10052399Term: Neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-006118-19-ITHutchison MediPharma Limited76
进行中（未招募）
1 期
An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europeeuroendocrine TumoursMedDRA version: 21.0Level: PTClassification code 10052399Term: Neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-006118-19-DEHutchison MediPharma Limited76